Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial
R. C. Reichman, G. J. Badger, G. J. Mertz, L. Corey, D. D. Richman, J. D. Connor, D. Redfield, M. C. Savoia, M. N. Oxman, Y. Bryson and al. et
Two hundred fifty patients were entered into a multicenter trial to
evaluate the efficacy and toxicity of orally administered acyclovir for
treatment of recurrent genital herpes. The study consisted of part A, in
which patients entered the study within 48 hours of the onset of lesions,
and part B, in which patients self-initiated therapy as soon as possible
after the onset of a recurrent episode. In both parts, patients received
either acyclovir (200 mg) or placebo, five times daily for five days. In
both parts, the duration of virus shedding and the time to crusting and
healing of lesions were shorter among acyclovir recipients than among
placebo recipients. In part B, fewer acyclovir recipients formed new
lesions during the study medication period than did placebo recipients.
When parts A and B were compared directly, the duration of virus shedding
and the times required for crusting and healing of lesions were
significantly shorter among acyclovir recipients in part B than among
acyclovir recipients in part A. No significant differences in the duration
of itching and pain or in the times of subsequent recurrence were noted
between acyclovir and placebo groups in either part A or part B. No
significant toxic or adverse reactions were seen in acyclovir recipients.
Oral acyclovir shortens the duration of virus shedding and the duration of
lesions in patients with recurrent genital herpes. These effects are more
pronounced when therapy is self-initiated by patients early in the course
of a recurrent episode.
The Treatment of Herpes Simplex Infections: An Evidence-Based Review
Cernik et al.
Arch Intern Med 2008;168:1137-1144.
ABSTRACT
| FULL TEXT
Modelling the cost per ulcer treated of incorporating episodic treatment for HSV-2 into the syndromic algorithm for genital ulcer disease
Vickerman et al.
Sex. Transm. Infect. 2008;84:243-248.
ABSTRACT
| FULL TEXT
Herpes simplex virus type 2: epidemiology and management options in developing countries
Paz-Bailey et al.
Postgrad. Med. J. 2008;84:299-306.
ABSTRACT
| FULL TEXT
Effect of Resiquimod 0.01% Gel on Lesion Healing and Viral Shedding When Applied to Genital Herpes Lesions
Fife et al.
Antimicrob. Agents Chemother. 2008;52:477-482.
ABSTRACT
| FULL TEXT
Herpes simplex virus type 2: epidemiology and management options in developing countries
Paz-Bailey et al.
Sex. Transm. Infect. 2007;83:16-22.
ABSTRACT
| FULL TEXT
Estimating the costs and benefits of screening monogamous, heterosexual couples for unrecognised infection with herpes simplex virus type 2
Fisman et al.
Sex. Transm. Infect. 2003;79:45-52.
ABSTRACT
| FULL TEXT
Herpes Simplex Virus Resistance to Acyclovir and Penciclovir after Two Decades of Antiviral Therapy
Bacon et al.
Clin. Microbiol. Rev. 2003;16:114-128.
ABSTRACT
| FULL TEXT
Aborted genital herpes simplex virus lesions: findings from a randomised controlled trial with valaciclovir
Strand et al.
Sex. Transm. Infect. 2002;78:435-439.
ABSTRACT
| FULL TEXT
Effects of Antiviral Usage on Transmission Dynamics of Herpes Simplex Virus Type 1 and on Antiviral Resistance: Predictions of Mathematical Models
Lipsitch et al.
Antimicrob. Agents Chemother. 2000;44:2824-2835.
ABSTRACT
| FULL TEXT
Antiviral Drugs
Balfour
NEJM 1999;340:1255-1268.
FULL TEXT
MRI follow-up of herpes simplex virus (type 1) radiculomyelitis
Kuker et al.
Neurology 1999;52:1102-1102.
FULL TEXT
A Multicenter Phase I/II Dose Escalation Study of Single-Dose Cidofovir Gel for Treatment of Recurrent Genital Herpes
Sacks et al.
Antimicrob. Agents Chemother. 1998;42:2996-2999.
ABSTRACT
| FULL TEXT
A Randomized, Placebo-Controlled Comparison of Oral Valacyclovir and Acyclovir in Immunocompetent Patients With Recurrent Genital Herpes Infections
Tyring et al.
Arch Dermatol 1998;134:185-191.
ABSTRACT
| FULL TEXT
Treatment of herpes simplex gingivostomatitis with aciclovir in children: a randomised double blind placebo controlled study
Amir et al.
BMJ 1997;314:1800-1800.
ABSTRACT
| FULL TEXT
Acyclovir in recurrent herpes labialis
Worrall
BMJ 1996;312:6-6.
FULL TEXT